Match!
Francesco Gelsomino
University of Bologna
70Publications
13H-index
592Citations
Publications 70
Newest
#1Francesco GrossiH-Index: 29
#2Carlo GenovaH-Index: 12
Last.Enrico CortesiH-Index: 32
view all 22 authors...
Source
Source
#2Lorena Incorvaia (University of Palermo)H-Index: 11
Last.Giuseppe Badalamenti (University of Palermo)H-Index: 19
view all 20 authors...
Source
#1Francesco GelsominoH-Index: 13
#2Giuseppe LambertiH-Index: 3
Last.Andrea ArdizzoniH-Index: 48
view all 7 authors...
Abstract Small cell lung cancer (SCLC) was defined as a “recalcitrant cancer” because of its dismal prognosis and lack of outcome improvements in the last 30 years. Immunotherapy with checkpoint inhibitors revolutionized treatment in many cancer types and results from the IMpower133 study, a double-blind placebo-controlled phase III trial, showed overall survival benefit for atezolizumab when added to standard platinum-etoposide chemotherapy in first-line SCLC setting for the first time since ye...
Source
#1Francesco GelsominoH-Index: 13
#2Marcello TiseoH-Index: 31
Last.A. ArdizzoniH-Index: 5
view all 9 authors...
Source
#1Marika Cinausero (University of Udine)H-Index: 7
#2Noemi Laprovitera (UNIBO: University of Bologna)H-Index: 1
Last.A. ArdizzoniH-Index: 5
view all 15 authors...
Source
#1Giulia Mazzaschi (University of Parma)H-Index: 3
Last.Marcello Tiseo (University of Parma)H-Index: 31
view all 15 authors...
Abstract Introduction A prospective investigation of the circulating immune profile in NSCLC patients receiving nivolumab was performed to identify potentially predictive parameters. Methods Flow Cytometry of peripheral blood (PB) CD3+, CD8+, CD4+, NK, Treg and MDSCs was prospectively performed in 31 consecutive advanced NSCLC patients at baseline (T0) and after 2 (T1) and 4 (T2) cycles of bi-weekly nivolumab. Functional molecules (PD-1, CD3ζ, Granzyme B, Perforin), cell proliferation (Ki67) and...
2 CitationsSource
#1Francesco GelsominoH-Index: 13
#2Giancarlo FacchiniH-Index: 6
Last.Andrea Ardizzoni (UNIBO: University of Bologna)H-Index: 48
view all 7 authors...
Source
#1Elisa Capizzi (UNIBO: University of Bologna)H-Index: 10
#2Costantino Ricci (UNIBO: University of Bologna)H-Index: 3
Last.Andrea Ardizzoni (UNIBO: University of Bologna)H-Index: 48
view all 11 authors...
Abstract Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the administration as first-line therapy of the anti PD-1 check-point inhibitor Pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC). Currently, only formalin-fixed paraffin-embedded samples are acceptable for PD-L1 immunostaining with the anti-PD-L1 antibodies 22-C3 and SP263. We investigated retrospectively the accuracy of the anti PD-L1 antibodies 22-C3, 28-28, SP263 in 50 p...
5 CitationsSource
Lung cancer remains the main cause of cancer-related death worldwide (1). In the last decade, the most significant improvements in non-small cell lung cancer (NSCLC) have been made through identification and exploiting of novel therapeutic targets. Among them, sensitizing EGFR mutations, ALK and ROS-1 gene rearrangements are the main targetable alterations that have deeply changed both clinical management and outcomes of these patients. Furthermore, the new antibody agents directed against progr...
Source
1234567